Compare the best healthcare stocks, get the most updated comparison by key indicators and discover each stock’s price target as well as recommendations by top Wall Street experts.

Compare up to 7 stocks

Clear

PFE NVS MRK JNJ RHHBY

Comparison Results

PFEPfizer

$40.05

-0.06 (-0.15%)

$43.10

(7.62% Upside)

224.19B

20.30

15.56%

1Buy

10Hold

0Sell

Hold

NVSNovartis

$88.70

0.15 (0.17%)

$104.08

(17.34% Upside)

199.14B

25.50

7.54%

3Buy

1Hold

1Sell

Moderate Buy

MRKMerck & Company

$79.38

-0.49 (-0.61%)

$89.43

(12.66% Upside)

200.99B

28.40

1.37%

5Buy

2Hold

0Sell

Moderate Buy

JNJJohnson & Johnson

$170.45

0.06 (0.04%)

$190.40

(11.70% Upside)

448.86B

30.10

16.14%

4Buy

1Hold

0Sell

Strong Buy

RHHBYRoche Holding

$42.72

0.52 (1.23%)

―

291.56B

18.10

-4.76%

0Buy

1Hold

0Sell

Hold

Performance Comparison

Compare the performance , dividend, and cannabis stocks. Go to the Stock Comparison tool to compare more stocks on key indicators.

Healthcare Stocks Latest News

FDA Gives Emergency Use Nod to Pfizer/BioNTech COVID-19 Vaccine in Adolescents

Pfizer (PFE) and BioNTech (BNTX) have received emergency use authorization (EUA) from the U.S. Food and Drug Administration...

Kailas SalunkheMay 11, 2021

PFE

J&J Vision Receives Approval For TECNIS Synergy And TECNIS Synergy Toric II IOLs In US And Canada

Johnson & Johnson Vision (JNJ) has received approval in the US for TECNIS Synergy and TECNIS Synergy Toric...

Kailas SalunkheMay 07, 2021

JNJ

Pfizer Stock Looks Healthy At Current Levels

On Tuesday, pharma giant Pfizer (PFE) reported a standout quarter. The results contrasted those of most other large-cap pharma...

Tom TaulliMay 06, 2021

PFE

Pfizer Reports Better-Than-Expected 1Q Results, Lifts COVID-19 Vaccine Sales Outlook

Pfizer (PFE) posted better-than-expected 1Q results driven by strong business performance and contributions from BNT162b2, the Pfizer COVID-19...

Priti RamgarhiaMay 04, 2021

PFE

Merck Reports Disappointing 1Q Results; Street Maintains A Strong Buy

Merck (MRK) reported disappointing first quarter results on Thursday with sales of $12.1 billion falling 1%, excluding the...

Shrilekha PetheApr 30, 2021

MRK

Johnson & Johnson Earnings Preview: Here’s What You Need To Know

Johnson & Johnson is slated to report first-quarter 2021 earnings on April 20 before the market opens. Over...

Priti RamgarhiaApr 20, 2021

JNJ

Johnson & Johnson’s Vaccine Pain Could Be Moderna’s and Pfizer’s Vaccine Gain

By now you’ve heard the news. On Tuesday, April 13, the U.S. Centers for Disease Control and Food...

TipRanks TeamApr 14, 2021

AZN JNJ PFE

Pulmatrix Will Regain Full Rights To PUR1800 After Termination Of Licensing Agreement; Shares Fall 16%

Pulmatrix is poised to regain full rights to its narrow spectrum kinase inhibitor (NSKI), including PUR1800. Johnson &...

Neha GuptaApr 13, 2021

JNJ PULM

Cidara Inks Licensing and Collaboration Deal With J&J’s Janssen For Influenza Antiviral CD388

Cidara Therapeutics has entered into a worldwide licensing and collaboration deal with Janssen Pharmaceuticals, a unit of Johnson...

Shrilekha PetheApr 06, 2021

JNJ CDTX

Johnson & Johnson Signs Single-Shot COVID-19 Vaccine Deal With AVAT

Janssen Pharmaceutica NV, a Johnson & Johnson company has inked a deal with the African Vaccine Acquisition Trust...

Priti RamgarhiaMar 29, 2021

JNJ

Read the latest stock news and analysis from the TipRanks news team.

See All News >

Recent Analysts Ratings of Healthcare Stocks

MRKMerck & Company

Premium

Buy

Premium

Reiterated

2021-05-18

PFEPfizer Inc

Premium

Hold

Premium

Reiterated

2021-05-12

NVSNovartis AG

Premium

Sell

Premium

Reiterated

2021-04-28

JNJJohnson & Johnson

Premium

Buy

Premium

Assigned

2021-04-21

RHHBYRoche Holding AG

Premium

Hold

Premium

Downgraded

2021-03-05

PFEPfizer Inc

Premium

Hold

Premium

Downgraded

2021-05-11

PFEPfizer Inc

Premium

Hold

Premium

Reiterated

2021-05-11

PFEPfizer Inc

Premium

Hold

Premium

Reiterated

2021-05-10

MRKMerck & Company

Premium

Buy

Premium

Reiterated

2021-05-05

PFEPfizer Inc

Premium

Hold

Premium

Reiterated

2021-05-05

All Ratings >

Most Recent Earnings of Healthcare Stocks

PFEPfizer

May 04, 2021

2021 (Q1)

0.78/0.86

0.606

42.08% (+0.26)

NVSNovartis

Apr 27, 2021

2021 (Q1)

1.54/―

0.958

―

MRKMerck & Company

Apr 29, 2021

2021 (Q1)

1.61/1.25

1.264

-1.03% (-0.01)

JNJJohnson & Johnson

Apr 20, 2021

2021 (Q1)

2.34/2.32

2.17

6.87% (+0.15)

RHHBYRoche Holding

Feb 04, 2021

2020 (Q4)

1.28/1.00

0.721

38.14% (+0.28)

Healthcare Stocks - FAQ

Which Healthcare stocks have a "Strong Buy" analyst rating?

These Healthcare stocks currently have a "Strong Buy" analyst rating consensus:

Johnson & Johnson - Strong Buy, based on 5 analyst ratings, 4 Buy, 1 Hold, and 0 Sell.

Are Healthcare stocks overpriced?

Pfizer's stock price is currently $40.05, and its average 12-month price target is $43.10.

Novartis's stock price is currently $88.70, and its average 12-month price target is $104.08.

Merck & Company's stock price is currently $79.38, and its average 12-month price target is $89.43.

Johnson & Johnson's stock price is currently $170.45, and its average 12-month price target is $190.40.

Roche Holding's stock price is currently $42.72, and its average 12-month price target is N/A.

Which Healthcare stocks pay dividends?

Pfizer does not currently pay dividends.

Novartis does not currently pay dividends.

Merck & Company does not currently pay dividends.

Johnson & Johnson currently pays a dividend of $1.06 which represents an annual dividend yield of 2.37%. Johnson & Johnson's next Ex-dividend date is May 24, 2021 and its next payout date is June 8, 2021.

Roche Holding does not currently pay dividends.